| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
N‑Stearoyl Taurine activates members of the transient receptor potential (TRP) family of calcium channels, acting as an endogenous lipid signaling molecule. It is classified as a mouse metabolite. Its mechanism involves binding to and modulating TRP channels, leading to calcium influx and downstream signaling effects. The compound belongs to the N‑acyl taurine family, which are recognized as a novel class of bioactive lipids.
|
|---|---|
| ln Vitro |
In vitro, N‑Stearoyl Taurine is used to study calcium channel activation. It induces calcium influx in cells expressing TRP channels, as measured by fluorescent calcium indicators (e.g., Fluo‑4). The compound has been isolated from rat brain and identified through lipidomics profiling, confirming its presence as an endogenous signaling molecule. It serves as a standard in LC‑MS methods for the detection of N‑acyl taurines in biological samples.
|
| ln Vivo |
In vivo, N‑Stearoyl Taurine is an endogenous metabolite present in rat brain and kidney, suggesting a physiological role in these tissues. As a mouse metabolite, it may be involved in local calcium signaling and nociception. It is not administered exogenously as a therapeutic; rather, its levels are measured in rodent models to understand its role in lipid signaling and metabolic regulation.
|
| Enzyme Assay |
The interaction of N‑Stearoyl Taurine with TRPV1 channels can be assessed using a calcium flux assay in a cell‑free membrane system. TRPV1‑expressing cell membranes are immobilized on a 96‑well plate. N‑Stearoyl Taurine (0.1-100 uM) is added, and calcium influx is measured using a fluorescent calcium indicator (e.g., Fluo‑4, λ_ex 485 nm, λ_em 525 nm) with a plate reader. The increase in fluorescence relative to control is quantified. Capsaicin (1 uM) is used as a positive control.
|
| Cell Assay |
N‑Stearoyl Taurine can be added to cultured neuronal cells (e.g., dorsal root ganglion neurons) at concentrations of 1-50 uM. Intracellular calcium levels are measured using Fluo‑4 AM loading (2 uM, 30 min, 37degC). Fluorescence intensity is recorded in a plate reader or by confocal microscopy. The percentage of cells showing calcium transients is calculated, and the EC₅0 for TRP channel activation is determined. Ruthenium red (10 uM) is used as a TRPV1 antagonist to confirm specificity.
|
| Animal Protocol |
N‑Stearoyl Taurine is not administered to animals as a drug, but its endogenous levels are measured in animal models. For a typical study, rats are euthanized, and brain tissue (hippocampus, cortex) or kidney is dissected. Lipids are extracted using chloroform:methanol (2:1) containing internal standards. N‑Stearoyl Taurine is quantified by LC‑MS/MS in multiple reaction monitoring mode. Levels are compared between treatment groups (e.g., pain models, inflammatory models) to assess changes in endogenous N‑acyl taurine metabolism.
|
| ADME/Pharmacokinetics |
N‑Stearoyl Taurine is an endogenous metabolite; its pharmacokinetics are defined by its natural biosynthesis and degradation. It is formed by the conjugation of stearic acid with taurine via an amide bond. It circulates in low concentrations and is rapidly hydrolyzed by fatty acid amide hydrolase (FAAH). The half‑life in plasma is estimated to be short (<30 min). It is stored as a solution in methanol at −20degC and protected from light. The compound is stable for up to 2 years under these conditions.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are available for N‑Stearoyl Taurine. As an endogenous lipid metabolite, it is expected to have low acute toxicity at physiological concentrations. At high concentrations, it may cause calcium‑mediated cytotoxicity. The compound is for research use only; it is not for human or therapeutic use. Standard laboratory precautions should be used: wear gloves and safety goggles, avoid inhalation, and use in a well‑ventilated area.
|
| References | |
| Additional Infomation |
N-Stearyl taurine is a fatty acid-taurine conjugate derived from stearic acid. It plays a metabolic role in mice. Functionally, it is related to octadecanoic acid. It is the conjugate acid of N-stearoyl taurine (1-).
N‑Stearoyl Taurine is not a drug; it is a research biochemical. It is used as a standard in lipidomics for the detection of N‑acyl taurines, and as a tool for studying the role of fatty acid‑taurine conjugates in endocannabinoid signaling and TRP channel activation. It is also used in studies of kidney function and neuronal calcium signaling. The compound is a member of a novel class of endogenous signaling lipids, with potential implications for pain, inflammation, and metabolic regulation. |
| Molecular Formula |
C20H41NO4S
|
|---|---|
| Molecular Weight |
391.61
|
| Exact Mass |
391.275
|
| CAS # |
63155-80-6
|
| PubChem CID |
168274
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Index of Refraction |
1.480
|
| LogP |
5.65
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
26
|
| Complexity |
418
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCCCC(=O)NCCS(=O)(=O)O
|
| InChi Key |
LMIJIHJZVURGQK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H41NO4S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(22)21-18-19-26(23,24)25/h2-19H2,1H3,(H,21,22)(H,23,24,25)
|
| Chemical Name |
2-(octadecanoylamino)ethanesulfonic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5536 mL | 12.7678 mL | 25.5356 mL | |
| 5 mM | 0.5107 mL | 2.5536 mL | 5.1071 mL | |
| 10 mM | 0.2554 mL | 1.2768 mL | 2.5536 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
